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Abstract
In this chapter the following topics will be addressed: (1) actions of the cho-
linergic system in the nervous system, commenting on acetylcholine metabolism 
and acetylcholinesterase metabolism; (2) acetylcholinesterase inhibitors as sub-
title in this topic: pharmacological characterization of pyridostigmine bromide, 
mechanism of action, and therapeutic effect of the drug; (3) use of pyridostigmine 
bromide in Persian Gulf War; and (4) potential effect of pyridostigmine bromide in 
oxidative stress, addressing as subtitle the influence of pyridostigmine bromide on 
the superoxide-hydrogen peroxide imbalance model. Studies indicate that the inter-
action between pyridostigmine bromide and stressors could trigger genotoxicity, 
the mechanism associated with the induction of oxidative stress that leads to this 
side effect of this drug; however, this discussion needs to be better elucidated and 
may be more discussed as there is interaction between the pyridostigmine bromide 
and an endogenous oxidative imbalance caused by it or even by the possible interac-
tion of this with genetic variations present in the antioxidant metabolism.
Keywords: acetylcholinesterase inhibitor, oxidative stress, neurotoxicity,  
superoxide dismutase 2, neuromuscular junction
1. Introduction
Pyridostigmine bromide (PB) is a reversible acetylcholinesterase (AChE) 
inhibitor and the first line of choice for the treatment of symptoms associated with 
myasthenia gravis (MG) and other neuromuscular junction disorder prophylactic 
treatment in the Persian Gulf War, for prevention of post-traumatic stress and heat 
and pesticide exposure. However, evidence suggests that PB may be associated with 
Gulf War illness, characterized by the presence of fatigue, headaches, cognitive 
dysfunction, and respiratory, gastrointestinal, and musculoskeletal disorders [1–4]. 
However studies in animal models showed that if used without any association did 
not cause extensive cytotoxicity and genotoxicity to these animals. But the associa-
tion of these drugs with other chemical or even physical agents caused cellular 
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apoptosis and genotoxicity in animals. These studies would suggest that this toxicity 
caused in association was due to oxidative stress [5, 6].
2. Actions of the cholinergic system in the nervous system
Within the neurotransmitters acting on the body’s nervous system is the so-
called cholinergic system associated with the release of the acetylcholine (ACh) 
molecule in the synaptic cleft [7–10]. ACh is considered to be one of the major 
chemical neurotransmitters of the peripheral nervous system being released by all 
preganglionic, parasympathetic, and some sympathetic postganglionic fibers, as 
well as by motor neurons that project to the skeletal muscles. It was the researcher 
Otto Loewi who discovered this molecule when he observed in his study the 
release of a biochemical substance by the parasympathetic nerve endings, which 
he called ACh [8, 11].
In cholinergic synapses, cholinesterases are present, which consist of a class 
of enzymes that catalyze the hydrolysis of ACh in acetic acid and choline in the 
synaptic cleft, and thus allow the cholinergic neuron to return to its resting state 
after activation. The most common cholinesterases present in the synaptic cleft are 
butyrylcholinesterase (BuChE) and AChE [12].
Although they are evolutionarily similar, these enzymes differ in their distribu-
tion in tissues, their kinetic properties, and the specificity of their substrates. AChE 
is found most abundantly in the central nervous system (CNS), in the skeletal 
muscles, and in the erythrocyte membrane, while BuChE is mostly found in blood 
plasma and is therefore also known as plasma cholinesterase [13].
Acetylcholinesterase and BuChE exhibit structural similarities, with their amino 
acids having approximately 50% homology. The other 50% heterogeneity among 
amino acids is responsible for the selectivity differences of both the substrates and 
the inhibitors of these enzymes. AChE preferentially hydrolyzes ACh, whereas 
BuChE is less selective and acts by hydrolyzing both ACh and butyrylcholine 
(BuCh) in comparable amounts [14].
In general, AChE is an enzyme that acts by hydrolyzing ACh in precursor mol-
ecules by rapidly closing the signaling of this molecule in the post-synaptic neuron 
or target tissue. Thus, AChE is a target enzyme in the treatment of various diseases, 
since anticholinesterase drugs act via their inhibition (Figure 1) [7–10].
Acetylcholine plays a crucial role in controlling numerous physiological pro-
cesses in all divisions of the nervous system. However, it is also involved in various 
neurological and muscular dysfunctions. The apparently antagonistic action of ACh 
occurs due to the existence of different cholinergic receptors, which are present 
according to each type of target tissue. The knowledge of the various forms of ACh 
activity allowed the identification of causal mechanisms of several neuromorbidi-
ties associated with neuromotor plaque disorders, mainly related to changes in 
cholinergic receptors.
This knowledge, in turn, led to the development or understanding of the perfor-
mance of drugs related to the control of symptoms of neurological diseases through 
differential modulation of the cholinergic system [7, 8, 10]. Among the morbidities 
with etiophysiopathology associated with changes in cholinergic response, MG 
and other forms of myasthenic syndromes are prominent. In these diseases, AChE 
inhibitors are used to control clinical symptoms [16]. In addition to its role in MG, 
more recent studies indicate that ACh could be a key molecule in the progression 
and control of symptoms of other neurodegenerative diseases, such as Alzheimer’s 
disease and other types of dementia [17, 18]. Because of its very specific physi-
ological action, drugs associated with modulation of cholinergic neurons have also 
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been prophylactically used to prevent populations subject to exposure to molecules 
potentially used in biological warfare, such as sarin gas [19]. For this reason, studies 
involving pharmacology related to the cholinergic system are considered clinical 
and epidemiologically relevant, in addition to their action in MG.
2.1 Acetylcholinesterase inhibitors
Acetylcholinesterase inhibitory drugs are termed anticholinesterases, and these are 
therapeutically used to reverse the neuromuscular blockade promoted by depolarizing 
myorelaxants, in the treatment of neurological diseases such as MG and myasthenic 
syndrome, in smooth muscle atony, in strabismus, and in the treatment of symptoms 
of Alzheimer’s disease, among others. An anticholinesterase drug delays the degrada-
tion of ACh, so the neurotransmitter spends more time in the synaptic cleft, thus 
intensifying cholinergic transmission, as can be observed in Figure 2 [20–22].
Physostigmine, an alkaloid obtained from Physostigma venenosum L., was the 
first AChE inhibitor to be discovered. Thus, its cholinergic effects have been known 
for many years, and as early as 1923, the molecular structure of the active substance 
was elucidated. In 1929 Stedman demonstrated that the cholinomimetic effects of 
physostigmine were due to the reversible inhibition of AChE [24]. Although it is 
old, this drug is still in use and is currently used in the treatment of glaucoma and 
in cases of overdose by anticholinergic compounds, such as atropine, and tricyclic 
antidepressants such as amitriptyline [25]. Other drugs with inhibitory action of 
AChE have been developed, such as neostigmine and PB, which are simplified 
analog of physostigmine [20].
There are two classes of AChE inhibitors, based on their mechanism of action, 
and may be reversible or irreversible depending on the type of action with the active 
site of the drug. Reversible agents are still present in two groups: short-acting and 
intermediate-acting agents [26].
Figure 1. 
Synthesis, storage, release, and degradation pathways of acetylcholine. Source: adapted Rang et al. [15]. AChR, 
acetylcholine receptor; ACh, acetylcholine; AChE, acetylcholinesterase.
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Edrophonium, a quaternary ammonium compound that binds only to the 
anionic site of the enzyme, is one of the short-acting reversible anticholinesterases. 
The ionic bond formed is easily reversed, and the action of the drug is brief. It is 
mainly used as a diagnostic purpose, since the improvement of muscle strength 
observed with the use of an anticholinesterase is a characteristic of MG, but it does 
not occur when muscle weakness results from other causes [27]. In contrast, the 
anticholinesterases of intermediate duration include neostigmine, PB, and physo-
stigmine that are composed of quaternary ammonium of clinical importance [26].
In chemical terms, all of these drugs are carbamoyl esters, once acetyl esters, 
and have basic groups that bind to the anionic site. The transfer of the carbamyl 
group to the hydroxyl group of the serine from the esterase site occurs in the same 
way as with ACh, but the carbamylated enzyme undergoes hydrolysis much more 
slowly, taking minutes instead of microseconds. The anticholinesterase drugs are 
therefore hydrolyzed, but at an insignificant rate when compared to ACh, and the 
slow recovery of the carbamylated enzyme indicates that the action of these drugs is 
quite prolonged [12].
Irreversible anticholinesterases are compounds that have a pentavalent phos-
phorus containing a leaving group, such as fluoride, or an organic group. Upon 
binding the enzyme, this group is released, leaving the hydroxyl group of the serine 
of the enzyme phosphorylated. Most of these organophosphorus compounds have 
been developed to be used as a chemical weapon in the form of toxic gases, and as 
a pesticide, but also for clinical use. They interact only with the esterase site of the 
enzyme and do not have a cationic group. Ecotiopate is an exception, since it has a 
quaternary nitrogen group that also binds to the anionic site [12].
When AChE is in inactive phosphorylated form, this molecule is generally very 
stable. With drugs such as diflos, there is no appreciable hydrolysis, and the recovery 
of enzymatic activity depends on the synthesis of new molecules of the enzyme, a 
process that can take weeks. With other drugs like the ecotiopate, slow hydrolysis 
takes place in the course of a few days, so that its action is not strictly irreversible. 
The diflos and the parathion are apolar substances volatile with high lipid solubility, 
quickly absorbed through the mucous membranes and even through the integral 
skin and the cuticle of the insects. The use of these agents as a chemical weapon or 
as an insecticide is based on this property. The absence of a quaternary group that 
confirms specificity indicates that most of these drugs block other serine hydrolases, 
although their pharmacological effects stem mainly from inhibition of AChE [26].
Figure 2. 
Cholinergic synapse in the absence and in the presence of an AChE inhibitor. Source: adapted Araújo et al. [23]. 
AChE, acetylcholinesterase; ch, choline.
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Acetylcholinesterase inhibitors affect both peripheral, autonomic cholinergic 
synapses and CNS synapses. It is also important to note that some organophospho-
rus compounds are capable of producing a severe form of neurotoxicity leading 
to irreversible changes in the cholinergic system, especially triggering effects 
on autonomic cholinergic synapses. These implications mainly reflect increased 
ACh activity in parasympathetic postganglionic synapses (increased secretions of 
salivary, lacrimal, bronchial, and gastrointestinal glands, increased peristaltic activ-
ity, bronchodilation, bradycardia, hypotension, pupillary constriction, fixation of 
vision accommodation for near, drop in intraocular pressure). Larger doses are able 
to stimulate, and subsequently block, autonomic ganglia, producing complex auto-
nomic effects. Blockade when it occurs consists of depolarization blockade and is 
associated with accumulation of ACh in plasma and in organic liquids. Neostigmine 
and PB tend to affect neuromuscular transmission more than the autonomic 
system, while physostigmine and organophosphates show the opposite pattern. 
The reason for this disparity is not clear, but therapeutic use takes advantage of this 
partial selectivity [26].
The main effect of these drugs is under neuromuscular junction; they increase 
the force of the contraction of a muscle stimulated by means of its motor nerve, 
thanks to the repetitive discharge in the muscular fiber associated with a prolon-
gation of the action potential. Normally, ACh is hydrolyzed so quickly that each 
stimulus initiates only one action potential in the muscle fiber. However, when 
AChE is inhibited, there is a short series of action potential in the muscle fiber and, 
as a consequence, a greater tension. Much more important, however, is the effect 
produced when the transmission is blocked by a non-depolarizing blocking agent 
such as pancuronium. In this case, the addition of an anticholinesterase drug can 
dramatically restore transmission. When a large number of receptors are blocked, 
most ACh molecules will normally find AChE molecules and will be destroyed 
by them before reaching a vacant receptor. The inhibition of AChE gives ACh 
molecules a greater chance of finding a vacant receptor before being destroyed and 
as a consequence increases the action potential such that it reaches the threshold. 
Transmission does not occur in MG because there are very few ACh receptors, and 
in this case inhibition of AChE improves transmission [12].
Acetylcholinesterase inhibitors rarely fully induce symptom relief in myasthenic 
patients and do not affect disease progression; however, they may be sufficiently 
effective for proper management in certain patients with mild or purely ocular 
nonprogressive disease [28]. It is also important to note that people with MG are 
susceptible to presenting the so-called myasthenic crisis that involves weakness 
in respiratory muscles, upper airway muscles, or a combination of both muscle 
groups. Both inspiratory and expiratory respiratory muscles may be affected, 
manifesting as dyspnea. Respiratory dysfunction may also manifest as upper airway 
obstruction if bulbar or upper airway muscle weakness occurs. Signs of bulbar 
weakness include dysphagia, nasal regurgitation, nasal quality of speech, staccato 
speech, weakness of the mandible (closure of the mandible weaker than the open-
ing of the mandible), bifacial paresis, and weakness of the tongue. Weakness of the 
upper airways can lead to failure by oropharyngeal collapse or tongue obstruction 
by increasing the work of already fatigued respiratory muscles. In epidemiological 
terms, it is estimated that 2/3 of myasthenic patients who present with myasthenic 
crisis need to be intubated and receive mechanical ventilation [29].
On the other hand, patients who ingest excess AChE inhibitors like PB may 
precipitate a cholinergic crisis characterized as muscarinic and nicotinic toxicity. 
Symptoms include increased sweating, lacrimation, salivation and pulmonary 
secretions, nausea, vomiting, diarrhea, bradycardia, and fasciculations. Although 
the cholinergic crisis is an important consideration in the evaluation of the patient 
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in a myasthenic crisis, it is quite uncommon in these patients. In the case of 
suspected cholinergic crisis, AChE inhibitors should be significantly reduced or 
discontinued [29].
In Ref. [30], the author described in his work that the natural course of MG, 
using only anticholinesterase drugs, with no other type of treatment, showed remis-
sion of symptoms in 20% of the patients and mortality in 25%. However, various 
therapies that involve thymectomy, immunosuppression, infection control, and oth-
ers positively affect the natural history of the disease. Still in that decade, this author 
concluded that the mortality in patients with MG is practically zero and the great 
majority of the patients have normal life, thanks to the improvement in the assistive 
technology related to the management of myasthenic crisis.
2.2 Use of pyridostigmine bromide in Persian gulf war
The use of chemical warfare agents is one of the greatest threats in the world 
today. Chemical warfare is based on the use of substances with toxic properties 
that are capable of killing, for mass destruction, and causing severe damage to the 
environment. The most prominent and dangerous chemical warfare agents are 
neurotoxic organophosphates which, due to their high toxicity, are sufficient in 
small amounts to cause seizures and death [31].
One of the biggest reasons for the use of chemical weapons in war and terrorist 
actions is that this war strategy ends up being cheaper than conventional weapons 
such as bombs, projectiles, and explosives. For example, to kill all people in an area 
of  1 km2, the use of chemical weapons can cost approximately 40% less than if 
traditional weapons were used. The other reason is that chemical weapons, in addi-
tion to causing death quickly and efficiently, also cause psychological problems to 
those who can survive intoxication, thus being more worrisome than other weapons 
of war [32].
The agents of chemical warfare were used several times in wars since antiquity, 
although being agents is not well defined nor very efficient. Already several more 
effective toxic agents received major importance in 1915, when the German army 
sent gases like chlorine and mustard against French troops during the First World 
War, causing countless losses in the enemy army. From that date the development 
of neurotoxic agents was more intense for several armies. Before World War II, the 
German army began the development of the first neurotoxic organophosphates as 
chemical warfare agents, especially tabun, sarin, and soman. Nevertheless, these 
agents, as well as mustard gas and other toxic substances, were not used during 
World War II. In the 1950s, the neurotoxic organophosphates of the V family were 
developed, which are more toxic and persistent in the environment, being that the 
first, called VX, was developed in England. Later similar compounds were created, 
especially in the former Soviet Union [32].
One of the first countries to use neurotoxic organophosphates was Iraq, under 
Saddam Hussein’s command in the war against Iran between 1980 and 1988, leading 
to hundreds of deaths of Iranians [33]. In 1994, sarin was used in Japan against 
civilians in a terrorist attack that resulted in the death of 7 people and 200 intoxica-
tions [34, 35]. On the other hand, poisoning of American soldiers by sarin occurred 
during the Gulf War in 1991 [33]. Recently, chemical weapons were used in Syria, 
killing about 1300 people, especially civilians and children, making it one of the 
worst chemical weapon use events in the world.
Organophosphate, pesticides, carbamates, chemical agents such as sarin, and 
the drug PB all belong to a class of chemicals that inactivate the circulation of cho-
linesterase enzymes such as AChE, BuChE, paraoxonase, and neurotoxic esterase 
resulting in interference with the breakdown of ACh neurotransmitter among 
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other effects [36, 37]. Exposures lead to increased ACh in the brain and peripheral 
nerve endings, with overestimation resulting from cholinergic nerve receptors [38] 
and subsequent reduction of ACh available, as well as altered gene expression and 
late cognitive effects [39]. At high exposure doses, AChE inhibitors may be toxic 
or fatal and at lower doses may lead to long-term health effects [40], one of its 
mechanisms being oxidative stress [37]. The main symptoms secondary to AChE 
inhibition in people with deficiency in central and peripheral cholinergic function 
are similar to those reported by Gulf War illness soldiers, such as skeletal muscle 
fatigue, cognitive deficit, and gastrointestinal, sleep, and temperature regulation 
problems [1, 41].
Exposures to toxic agents in the Gulf War were considered contributors to 
numerous long-term health problems. Post-war effects include pesticide effects, 
uranium munitions, air contaminants from fires in Kuwait oil wells, and chemical 
nerve agents. PB was then used as a prophylactic measure against possible exposure 
to these nerve agents, and to other risks, such as psychologically stressful conditions 
and heat. A military who underwent several exposures in different combinations 
presented synergic effects that have not yet been determined in this population [4].
Gulf War illness is considered a chronic multi-symptom condition that affected 
25–32% of soldiers who operated in the Gulf War. It is clinically characterized by 
the presence of fatigue; headaches; cognitive, respiratory, and musculoskeletal 
dysfunction; and gastrointestinal disorders [1–4]. Inflammation and increased 
oxidative stress associated with mitochondrial dysfunction may negatively affect 
cognitive function and mood, either directly or indirectly, through the reduc-
tion of hippocampal neurogenesis [42–44]. Therefore, chronic inflammation and 
oxidative stress are likely to be among the leading causes of Gulf War illness brain 
dysfunction.
Studies were conducted to identify possible causal factors, and evidence has sug-
gested that PB may be associated with etiopathogenesis of Gulf War illness. One of 
the first studies carried out by [45] described the development of three syndromes 
associated with PB use: (1) impaired cognition, (2) confusion-ataxia, and (3) neu-
ropathy. However, complementary investigations have also suggested that the use 
of PB without any other chemical or physical stressor in neuronal cells of animals 
does not cause great damages, such as decreased viability and increased cellular 
apoptosis [8, 46]. Thus, it appears that the interaction of PB with other endogenous 
or exogenous factors is what would trigger the Gulf War illness.
2.3 Potential effect of pyridostigmine bromide in oxidative stress
Considering the results of epidemiological and in animal experiments, the data 
described so far reinforce the hypothesis that the interaction between PB and other 
drugs, such as organophosphates, or perhaps other stress factors, could contribute 
to the rupture of homeostasis neural, via amplification of oxidative stress and of 
chronic inflammatory conditions that would trigger systemic neural dysfunctions 
associated with Gulf War illness [42–44, 47–49].
In recent decades the role of reactive species in pathophysiological processes 
related to oxidative stress has been intensively investigated. The reactive species 
are molecules that contain one or more unpaired electrons in the last electron layer 
[50]. These reactive molecules are generally unstable and originate from oxygen, 
nitrogen, or sulfur [51]. When the generation of reactive species exceeds the anti-
oxidant capacity of the organism, an imbalance occurs in the cellular redox state, 
promoting oxidative stress and subsequent oxidative damage [52].
Mitochondria are the main site of reactive oxygen species (ROS) production 
[53]. Much of the energy produced in the body is generated through oxidative 
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phosphorylation. Therefore, paradoxically, a fundamental process for the develop-
ment of the life of eukaryotes (oxidative phosphorylation) is also one of the main 
responsible for the production of ROS. These species are also produced by other 
electron transfer reactions between different redox reactive agents, such as those 
involved in defense mechanisms against pathogens, for example, the case of nico-
tinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) [54].
The production of ROS in various metabolic processes plays an important role 
in the functioning of the organism. They are dose dependent, and some types of 
ROS when in low concentrations are considered important signaling molecules 
responsible for the transport of electrons in the respiratory chain [54]. ROS have a 
deleterious effect on the body when there is an excessive increase in its production 
or when there is a decrease in antioxidant agents. The three main types of ROS are 
superoxide anion (O2
•−), hydrogen peroxide (H2O2), and hydroxyl radical (OH
•).
Among the ROS, the O2
•− radical is the most common, abundant, and quite 
diffusible both inside and between cells in vivo, the first ROS being formed by the 
reduction of oxygen by a single electron during oxidative phosphorylation that 
occurs in the mitochondria [52]. It is a poorly reactive ROS and has no ability to pen-
etrate lipid membranes, thus acting only in the compartment where it is produced 
[55]. H2O2 is not a free radical, but an intermediate metabolite of oxygen, which in 
uncontrolled amounts becomes extremely deleterious, because it participates as an 
intermediate in the reaction that produces the OH• radical. H2O2 has long life and is 
able to cross biological membranes. The OH• radical is considered the most reactive 
ROS in biological systems, being capable of causing more damage than any other 
ROS. It is formed from H2O2, in a reaction catalyzed by transition metal ions (Fe
2+ or 
Cu+), called the Fenton reaction. This OH• radical can also initiate the oxidation of 
the polyunsaturated fatty acids of the cell membranes (lipoperoxidation) [55–57].
However, in order to maintain the balance in the ROS generation, there is the 
antioxidant system, but when the ROS are in excess and the antioxidant system 
cannot keep the balance, processes of damage to the organism can occur, and this 
situation of imbalance is denominated oxidative stress [58].
The antioxidant system has the function of inhibiting the oxidative damages 
caused by excess reactive species. These are divided into enzymatic or endogenous 
antioxidants and nonenzymatic or exogenous antioxidants, the latter being mainly 
acquired by the diet [59].
Nonenzymatic antioxidants include ascorbic acid (vitamin C), which inhibits 
the action of oxidized low-density lipoprotein (LDL) and protects against the 
action of ROS; phenolic acids; resveratrol; catechins; β-carotene (vitamin A), which 
protects against lipid peroxidation and damage to DNA; α-tocopherol (vitamin E); 
copper (Cu); zinc (Zn); and others. As for enzymatic antioxidants, we have super-
oxide dismutase (SOD), which facilitates the conversion of the radical O2
•− into 
H2O2; catalase (CAT), which converts H2O2 to O2 and H2O; and glutathione peroxi-
dase (GPx), which has the capacity to reduce H2O2 to H2O [60].
Oxidative stress is involved in several non-transmissible chronic diseases, such 
as atherosclerosis, hypertension, neurodegenerative diseases, cancer, and type II 
diabetes mellitus. In the latter, for example, excess reactive species have a detrimen-
tal influence on glucose uptake by muscle and adipose tissues, as well as decreasing 
insulin secretion, neuronal death, and apoptosis of various cells [61–64].
2.3.1  Influence of pyridostigmine bromide on the superoxide-hydrogen peroxide 
imbalance model
A large body of evidence suggests that oxidative stress is associated with cell 
aging, dysfunctions, and diseases [65]. However, it was long believed that ROS were 
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largely responsible for these deleterious processes. For this reason, about 20 years 
ago, studies were begun to investigate the beneficial health effects of supplementing 
large amounts of antioxidants. The results, surprisingly, were not good. In some 
studies, higher morbidity loads were reported in subjects supplemented with high-
dose vitamin than in the placebo group. The explanation for this apparent paradox 
soon emerged: many ROS, in low concentrations, were actually signaling molecules 
of various cellular functions. Among these, nitric oxide (NO) and H2O2 stand out, 
so the neutralization of these molecules by antioxidants influenced the cellular 
homeostasis processes [66].
It was hypothesized that maintenance of redox balance was a relevant aspect to 
avoid non-transmissible chronic morbidities or to decrease the side effects related 
to the ingestion of some drugs [67]. This hypothesis was tested and corroborated by 
genetic studies involving the imbalance of the endogenous antioxidant system. This 
is the case of the point polymorphism observed in the SOD2 enzyme gene called 
Val16Ala-SOD2 [68].
The enzyme SOD2 is synthesized from a nuclear gene located on chromosome 
6, subregion 6q25, which codes for a homotetramer which binds to a manganese ion 
per subunit. This protein structure synthesized in the rough endoplasmic reticulum 
is still enzymatically inactive and has a peptide sequence known as the mitochon-
drial target sequence (MTS) that directs SOD2 into the mitochondria. As it passes 
through the pores of the inner mitochondrial membrane, the MTS peptide segment 
is cleaved by lysosomes, and the mature protein aggregates into an active form, 
making it a functional SOD2 enzyme [69, 70].
Previous studies have identified a single nucleotide polymorphism (SNP) in the 
MTS region of the SOD2 gene, in which a thiamine (T) is replaced by a cytosine (C) 
in exon 2, nucleotide 47. Substitution affects the codon 16, which encodes for amino 
acid 9, mutating a valine (GTT) in an alanine (GCT), and hence the polymorphism 
is called Val16Ala-SOD2 [69]. Therefore, this polymorphism is associated with the 
presence of two alleles alanine (A) and valine (V) and three possible genotypes: 
AA, AV, and VV. In phenotypic terms, the Ala-SOD2 variant generates a protein 
with α-helix structure, thus being easily imported into the mitochondria. The Val-
SOD2 variant, on the other hand, generates a protein with a partial β-lamina struc-
ture, which causes the inactive SOD2 protein to be partially retained in the pores of 
the mitochondrial inner membrane, as it is being imported into the mitochondria. 
In the presence of the two alleles that form the heterozygous genotype, the Ala-/
Val-SOD2 protein presents helical structure [70, 71].
In vitro investigations have demonstrated that Ala-SOD2 is capable of generat-
ing SOD2 homotetramer with 30–40% greater enzymatic activity than the matrix 
processed with Val-SOD2 precursor [70]. Despite the increased efficiency of SOD2 
produced from the A allele, many epidemiological studies have described associa-
tion between this genetic variant and various types of cancer [72] including pros-
tate [73], breast [74], and lung [75] cancer.
It is believed that this phenomenon occurs due to the higher efficiency of SOD2 
that, if not accompanied by an increase in the levels of GPX and CAT, or of nonen-
zymatic antioxidant compounds stored in the cell, ends up generating excess H2O2 
that can react with transition metals via the Fenton reaction originating the strongly 
mutagenic OH• radical.
On the other hand, previous investigations related to the Val-SOD2 allele suggest 
that this allele and/or the VV genotype would increase the risk of some chronic non-
transmissible diseases and also differential response to xenobiotic agents [68]. In 
fact, the VV genotype has a lower enzymatic efficiency of SOD2 and thus poten-
tially leads to the basal accumulation of higher concentrations of the radical anion 
O2




This figure summarizes the Val16Ala-SOD2 polymorphism. This protein has a small peptide region known 
as the mitochondrial target sequence (MTS) that directs SOD2 protein into the mitochondria. Within this 
organelle, the enzyme SOD2 finally becomes active. This polymorphism causes a thymine to be exchanged for a 
cytosine at codon 16. This exchange leads to the substitution of the amino acid valine by the amino acid alanine. 
Thus, there are three possible genotypes related to this polymorphism: AA, VV, and AV. Source: adapted 
Barbisan et al. [93].
highly reactive in the presence of NO, which leads to the production of peroxyni-
trite (ONOO−). In turn, this molecule has great affinity with lipids, thus causing an 
extensive oxidation of cell membranes, a phenomenon known as lipid peroxidation 
or lipid peroxidation. In addition, the excess of the radical anion O2
•− can lead to the 
production of other ROS that contribute to establish oxidative stress states [76].
Thus, the VV-SOD2 genotype has been associated with endothelial dysfunction, 
elevated oxidized LDL levels [77], the presence of microvascular complications 
associated with diabetes including retinopathies and nephropathies [78], elevated 
levels of inflammatory cytokines [79, 80], increased risk of developing obesity [81], 
hypercholesterolemia [82], and association between dyslipidemia and stroke [83]. 
Although AA genotype increases the risk of breast cancer, in certain populations, 
VV genotype appears to amplify tumor aggressiveness as it increases the potential 
for breast cancer metastasis [84, 85].
In addition, in vitro investigations have also shown that Val16Ala-SOD2 poly-
morphism differentially affects the toxicity of lymphocytes exposed to ultraviolet 
radiation [86], to the methylmercury heavy metal [87], and the pharmacological 
response of hypercholesterolemic patients to rosuvastatin [88]. This polymor-
phism also altered the antioxidant response of peripheral blood mononuclear cells 
(PBMCs) exposed to resveratrol [89] and to seleno-l-methionine [90].
Due to the importance of this genetic polymorphism for human health, an 
experimental pharmacological model was developed by [91], for prostate cancer, 
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and by [92], for colorectal cancer, showing in tumor cells the difference in treat-
ment by superoxide-hydrogen peroxide (S-HP) imbalance.
In this S-HP pharmacological imbalance model, two molecules, paraquat and 
porphyrin, were used. Paraquat is an O2
•− anion generator, whose higher levels 
of this molecule are observed in VV-like cells. On the other hand, porphyrin is a 
molecule that acts similar to SOD2 (SOD2-like), thus causing an increase in H2O2 
levels, as observed in cells with the genotype AA-like [91, 92], simulating in vitro 
the two genotypes of the polymorphism. A schematic summary of this genetic 
polymorphism is illustrated in Figure 3.
In summary, considering that PB seems to interact with other exogenous pro-
oxidant agents, triggering symptoms recognized in Gulf War illness, the hypothesis 
of interaction between this drug and the Val16Ala-SOD2 polymorphism cannot be 
ruled out.
3. Discussion
Pyridostigmine bromide was used to treat changes in neuromuscular junction 
[21, 20] and was also used prophylactically in GWI for stress prevention and against 
chemical and physical agents, which soldiers were exposed to during the war [49]. 
However, this drug was associated with several adverse effects detected during and 
after the war in soldiers who prophylactically ingested 30 mg/3 times a day of this 
drug. Among these effects, the main ones were skeletal muscle fatigue, headache, 
attention deficit, cognition problems, gastrointestinal disorders, and sleep and 
temperature regulation problems, among other autonomic alterations [1, 2, 4].
These results suggested that BP could have a relevant cytotoxic effect on 
humans. However, previous animal cell studies have suggested that isolated expo-
sure to CP would not cause extensive damage including decreased cell viability and 
cellular apoptosis [8, 46]. However, other studies have shown that when animals 
were treated with CP associated with other chemical molecules that were potentially 
used in biological warfare or in the prophylaxis of other diseases or even parasitic 
diseases, such as permethrin, used to prevent infestation by head lice, results were 
quite different. These results then indicated the interaction of BP with chemical 
agents or even physical factors such as intense physical activity and psychological 
stress such as oxidative stress and inflammation [6].
Considering that most of the agents in which BP interacts are factors that 
increase oxidative stress and body inflammation, an open question concerns the 
potential occurrence of interaction between BP and oxidative imbalances associ-
ated with individuals’ genetic characteristics, as is the case of the Val16Ala-SOD2 
polymorphism. This question is quite pertinent since, so far, doubts remain about 
the efficacy and safety of the use of BP as a drug and also about the fact that it was 
pointed as the cause of GWI disease.
So two studies were very important that showed that pyridostigmine bromide 
affected in vitro cytogenotoxicity and AChE enzyme activity of SHSY-5Y neural 
cells, in a concentration-dependent manner, showing decreased cell viability, 
increased oxidative stress, and apoptosis mainly when they were exposed to the 
highest concentration tested at 80 ng/mL. However, over a longer period of expo-
sure, there was an increase in cell proliferation rate, suggesting that the oxidative 
effects triggered by CP exposure may be transient and reversible in these neural 
cells [94]. However, when exposed to different Val16Ala-SOD2 genotypes, the 
cytogenotoxicity and efficacy in inhibiting AChE induced by CP exposure were 
directly modulated by the Val16Ala-SOD2 polymorphism that alters the basal oxida-
tive state of human peripheral blood polymorphonuclear cells. In this case, cells 
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with higher basal production of H2O2 had higher cytotoxic sensitivity to CP, while 
cells with higher basal production of O2− anion showed higher resistance to inhibi-
tion of AChE enzyme. These results suggest a potential pharmacogenetic effect of 
S-HP imbalance on BP efficacy and safety [95].
These results found in the literature suggest that the efficacy and toxicity to 
CP are influenced by the interaction with oxidative imbalance by Val16Ala-SOD2 
polymorphism, indicating potential toxicogenetic and pharmacogenetic effects of 
this drug. The data presented here may potentially contribute to elucidate the inter-
action between BP and oxidative stress-inducing agents and may also be relevant 
to the clinical and epidemiological field related to the use of AChE inhibitors as 
therapeutic agents [94, 95].
4. Conclusion
Studies indicate that the interaction between pyridostigmine bromide and 
stressors could trigger genotoxicity, the mechanism associated with the induction 
of oxidative stress that leads to this side effect of this drug; however, this discus-
sion needs to be better elucidated and may be more discussed as there is interaction 
between the pyridostigmine bromide and an endogenous oxidative imbalance 
caused by it or even by the possible interaction of this with genetic variations pres-
ent in the antioxidant metabolism.
This chapter was developed to show studies related to the toxicity of pyridostig-
mine bromide and its influence with oxidative stress, as we conclude that:
Results suggested that the exposure of neural cells to PB without other chemical 
and physical stressors does not cause extensive toxicity that could explain the clini-
cal symptoms observed in GWI.
Study demonstrated that PB can transiently modulate redox metabolism in cells. 
However, factors that increase HP levels, such as the AA-SOD2 genotype, may affect 
PB efficiency and efficacy by inducing AChE inhibition and oxidative stress. Data 
from these in vitro studies may be useful for complementing population studies 
investigating PB or other AChE inhibitors.
Our results suggest that the efficacy and toxicity to CP are influenced by the 
toxicogenetic and pharmacogenetic interactions of this drug. The results presented 
here may potentially contribute to elucidate the interaction between CP and oxida-
tive stress-inducing agents and may also be relevant to the clinical and epidemio-
logical field related to the use of AChE inhibitors as therapeutic agents.
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